Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbvie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbvie

Global HUMIRA revenues were $4.7 billion, up 6% in the quarter.

By: Contract Pharma

Contract Pharma Staff

Abbvie
1Q Revenues: $8.6 billion (+ 10%)
1Q Earnings: $3.0 billion (+23%)
Comments: Global HUMIRA revenues were $4.7 billion, up 6%, with U.S. revenues of $3.7 billion, an increase of 14%, and international sales of $1.0 billion, down 15% due to biosimilar competition. Global revenues from the hematologic oncology portfolio were $1.5 billion, up 32%, with IMBRUVICA revenues of $1.2 billion, up 21%. Global VENCLEXTA revenues were $317 million. SKYRIZI revenues were $300 million and RINVOQ revenues were $86 million. HCV drug Mavyret sales were down 29% to $559 million. Creon sales were $276 million, up 22%. Lupron sales were $233 million, up 2%. Synthroid sales were up 12% to $205 million. Synagis sales were down 6% to $270 million. Duodopa sales were $124 million, up 12%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters